

# Exemestane

Catalog No: tcsc1766



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

107868-30-4

**Formula:**

$C_{20}H_{24}O_2$

**Pathway:**

Others

**Target:**

Aromatase

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 54$  mg/mL (182.19 mM)

**Alternative Names:**

FCE 24304;EXE

**Observed Molecular Weight:**

296.4

## Product Description


Exemestane(FCE 24304) is an aromatase inhibitor, inhibits human placental and rat ovarian aromatase with IC<sub>50</sub> of 30 nM and 40 nM, respectively.

Target: Aromatase

Approved: October 2005

Exemestane competitively inhibits and time-dependently inactivates of human placental aromatase with K<sub>i</sub> of 4.3 nM. Exemestane displaces [3H]DHT from rat prostate androgen receptor with IC<sub>50</sub> of 0.9 μM [1]. Exemestane (1 μM) increases alkaline phosphatase activity in hFOB and Saos-2 cells and induces the expression of MYBL2, OSTM1, HOXD11, ADCYAP1R1, and glypican 2 in hFOB cells [2]. Exemestane causes aromatase degradation in a dose-responsive manner in MCF-7aro cells [3].

Exemestane increases lumbar spine BMD by 14.0% in OVX rats at dose of 100 mg/kg. Exemestane (100 mg/kg) and 17-hydroexemestane (20 mg/kg) significantly reduces an ovariectomy-induced increase in serum pyridinoline and serum osteocalcin in rats and causes significant reductions of serum cholesterol and low-density lipoprotein cholesterol in OVX rats [4]. Exemestane (20 mg/kg/day s.c.) induces 26% complete (CR) and 18% partial (PR) tumor regressions in rats with 7,12-dimethylbenzanthracene (DMBA)-induced mammary tumors [5].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!